FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
Jul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
News Release - Eli Lilly and Company
Jul 2, 2024 · Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months.
FDA approves treatment for adults with Alzheimer’s disease
Jul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
FDA approves Eli Lilly's Alzheimer's drug Kisunla - NBC News
The drug, donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. The FDA cleared the drug for use in adults with mild cognitive ...
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly - CBS News
Jul 3, 2024 · Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the experimental Alzheimer's treatment to market, despite promising clinical trial...
FDA approves a second Alzheimer's drug that can modestly slow …
Jul 3, 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to...
Alzhiemer's drug Kisunla from Eli Lilly gains FDA approval - USA TODAY
Jul 2, 2024 · Kisunla becomes the third amyloid-clearing Alzheimer's drug approved since 2021. Last year, the FDA approved Eisai and Biogen's drug Leqembi but required the drug to provide a...
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study
Nov 8, 2024 · That’s according to the findings of an ongoing Phase 3 clinical study, dubbed TRAILBLAZER-ALZ 6 (NCT05738486), that’s testing the safety of different dosing regimens of Kisunla in adults with early Alzheimer’s.The participants are administered one of four dosing regimens of Eli Lilly’s Kisunla, interspersed with periods in which they receive a placebo, over 24 weeks, or nearly six months.
New Drug Approved for Early Alzheimer’s - The New York Times
Jul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.